Clinical trial NCT02645409: Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Official title: Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Cell Carcinoma
Keywords: Fluorescence
Imaging
Partial nephrectomy
Radical nephrectomy
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2016-01-01
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary

• To explore the use of OTL38 and fluorescence imaging to detect RCC in partial nephrectomy at the margins of resection, and in lymph node(s) or other metastases during radical nephrectomy.

Detailed description: Administration of the study drug, OTL38, will begin prior to skin incision in the preoperative area where safety monitoring will occur. The tumor resection occurs approximately 2 hours after being brought back to the operating room and so there is no wait time between infusion and being taken back to operating room. Intraoperative fluorescent imaging will be utilized in parallel with the standard operating procedure to capture images during surgery. Images also will be taken of the excised specimen on the back table. The excised specimen will be sent to the pathology department for fluorescent imaging and immunohistochemistry for FR. Subjects will have a 2-5 day hospital stay (normal nephrectomy recovery period) where safety measurements will be taken. Final safety measurements will be taken at the 10-day and 1-month follow-up visits.

Eligibility criteria: Inclusion criteria for localized RCC treated with partial nephrectomy

To be considered eligible to participate in this study, a patient must meet all the inclusion criteria listed below:

* ≥ 18 years of age.
* Have primary or suspected diagnosis of RCC, with presence of cT1-2 renal mass by diagnostic CT assessment.
* Scheduled for partial nephrectomy of renal mass.
* Expected survival of at least 3 months.
* Written informed consent available.
* ECOG ≤ 1 (Appendix G).
* Negative serum or urine pregnancy test within 24 hours for females of child bearing age
* Recovered from toxicity of any prior therapy to ≥ grade 1.

Inclusion criteria for advanced RCC treated with radical nephrectomy

To be considered eligible to participate in this study, a patient must meet all the inclusion criteria listed below:

* ≥ 18 years of age.
* Have pathologic or suspected diagnosis of RCC with presence of cT1-4 renal mass and evidence of nodal or metastatic involvement by diagnostic CT assessment
* Scheduled for radical nephrectomy and lymph node dissection.
* Expected survival of at least 3 months.
* ECOG ≤ 2.
* Negative serum or urine pregnancy test within 24 hours for females of child bearing age.
* Recovered from toxicity of any prior therapy to ≥ grade 1
* Written informed consent available.

Exclusion criteria for both localized and advanced RCC

* History of any anaphylactic reaction, any severe allergy, or any allergy to folate.
* Brain metastases
* Baseline GFR \< 50 mL/min/1.73m2)
* Hepatic toxicity ≥ Grade 2 (using CTCAE version 4 standard definitions).
* Participation in another investigational drug trial either concurrently or 30 days prior to surgery
* Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient, limit the patient's ability to complete the study, and/or compromise the objectives of the study.
* Known sensitivity to fluorescent light

Primary outcomes:
measure: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens
timeFrame: During procedure, an average of 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University Health Hospital
state: Indiana
city: Indianapolis
country: United States
facility: Indiana University Health Melvin and Bren Simon Cancer Center
state: Indiana
Study officials:
affiliation: Indiana University School of Medicine, Indiana University Simon Cancer Center
name: Chandru P. Sundaram, MD
role: PRINCIPAL_INVESTIGATOR
References: